Skip to content

Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Qingkepingchuan Granules Clinical Observation of Phlegm-Heat and Lung Depletion

Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Qingkepingchuan Granules Clinical Observation of Phlegm-Heat and Lung Depletion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06143358
Enrollment
100
Registered
2023-11-22
Start date
2022-01-01
Completion date
2023-07-07
Last updated
2023-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Through the clinical observation of Qingcheng Pingxian Granules in the treatment of acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat lung syndrome), (1) to evaluate the safety of Qingcheng Pingxian Granules in the acute exacerbation of chronic obstructive pulmonary disease; (2) to observe the clinical efficacy of Qingcheng Pingxian Granules in the treatment of acute exacerbation of chronic obstructive pulmonary disease, to provide an effective medication and solution for the treatment of acute exacerbation of chronic obstructive pulmonary disease, and to provide data for the development of the further application of Qingcheng Pingxian Granules.

Interventions

DRUGQingkepingchuan Granules

Qingkepingchuan Granules,Take it three times a day with water after meals.

OTHERconventional treatment

Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments

Sponsors

Zhang Zhijie
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Qingkepingchuan Granules

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Meet the diagnostic criteria of AECOPD. 2. Chinese medicine diagnosis is consistent with phlegm-heat and lung depletion evidence 3. 40 years old ≤ age ≤ 90 years old 4. Patients who signed the informed consent form and volunteered to participate in the study

Exclusion criteria

1. Combined with other primary lung diseases such as bronchial asthma, bronchiectasis, etc. 2. Combination of serious cardiovascular, urinary, digestive, haematopoietic, endocrine metabolic system diseases, other psychiatric and neurological diseases. 3. Pregnant or lactating patients. 4. Allergic to the clinical trial drugs.

Design outcomes

Primary

MeasureTime frameDescription
Chinese Medicine Symptoms ScaleBefore the start of treatment, 1 week of treatment, 2 weeks of treatment, 1 month of follow-upRecord changes in patients' TCM indicators。The scale includes cough, wheezing, shortness of breath, sputum volume, chest tightness, sputum colour, sputum quality, fever, thirst, irritability, constipation, tongue coating, and pulse. The first four items are rated 0-6, and the last nine items are rated 0-3, with higher ratings indicating poorer treatment outcomes.
COPD assessment testBefore the start of treatment, 1 week of treatment, 2 weeks of treatment, 1 month of follow-upRecord changes in the patient's condition
breathlessness measurement using the modified British Medical Research CouncilBefore the start of treatment, 1 week of treatment, 2 weeks of treatment, 1 month of follow-upRecord changes in the patient's condition

Secondary

MeasureTime frameDescription
6-minute walking testBefore the start of treatment, 2 weeks of treatmentRecord changes in the patient's condition

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026